Is Nirmatrelvir/Ritonavir combination on the market?

In December 2021, the U.S. Food and Drug Administration (FDA) granted emergency use authorization for the Nirmatrelvir/Ritonavir tablet combination, trade name Paxlovid, which is a co-packaged product containing Nirmatrelvir and Ritonavir for the treatment of certain patients with mild to moderate COVID-19. The nematvir/ritonavir tablet combination was fully approved by the FDA on May 25, 2023.

NematrevirThe Nematrevir/ritonavir tablet combination was approved in Canada in January 2022 for the treatment of adult patients with mild to moderate novel coronavirus infection, and subsequently received conditional marketing authorization from the European Medicines Agency (EMA). It is believed that its benefits outweigh its risks. The nematvir/ritonavir tablet combination was approved by the National Medical Products Administration for marketing in China in February 2022 as an oral small molecule novel coronavirus treatment drug for the treatment of mild to moderate novel coronavirus pneumonia (COVID-19) in adults with high risk factors for progression to severe disease.

Since the nematvir/ritonavir tablet combination has been on the market for a short time and has not been included in the medical insurance, the domestic price has not yet been determined. The original drug of nematvir/ritonavir tablet combination marketed overseas, the specification is nematvir 150mg + ritonavir 100mg)*30 tablets per box, the price may be around 2,000 yuan (the price may fluctuate due to the exchange rate), India The price of each box of the generic Nematvir/Ritonavir tablet combination produced by the pharmaceutical factory may be around RMB 1,000 (the price may fluctuate due to the exchange rate). The ingredients of the two drugs are basically the same. For more drug information and specific prices, please consult Yaode Medical Consultant.